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X-ray screening seems to reduce gastric cancer mortality by half
in a community-controlled trial in Costa Rica
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X-ray screening of gastric cancer is broadly used in Japan, although no controlled trial has proved its effectiveness. This study evaluates
the impact of an X-ray screening demonstrative intervention to reduce gastric cancer mortality in a Costa Rican region. The
evaluation follows a quasi-experimental, community-controlled design, with measures before and after. About 7000 individuals
participated by invitation in the two-wave screening programme. X-ray screening was followed by videoendoscopy and gastric
biopsies. Treatment included resection with or without lymph node dissection. Comparisons with two control groups estimate that
gastric cancer mortality was halved in the period from 2 to 7 years after the first screening visit. Validity of X-rays as used in this
intervention had 88% sensitivity, 80% specificity, and 3% predictive value for individuals with two screening visits. Incidence in the
screened group increased up to four times. Case survival was 85% in the intervention group after 5 years, compared to 12% among
the controls before the intervention and 35% among the controls in the same region after the intervention. Although X-ray mass
screening seems able to reduce stomach cancer mortality, its high cost may be an obstacle for scaling up this intervention in a non-
rich country like Costa Rica.
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Gastric cancer is the second highest cause of cancer death
worldwide (Parkin et al, 2001). The therapy of this cancer is early
extirpation, whose outcome is closely related to the stage of disease
progression. Japan, the country with the highest incidence in the
world, has been broadly using X-ray screening to pick early gastric
tumours since the 1960s (Inaba et al, 1999; Tsubono and
Hisamichi, 2000). Some pilot programmes elsewhere sporadically
used this Japanese technique as well (Llorens, 1991; Pisani et al,
1994). The effectiveness of this intervention is, however, con-
troversial as it was in the past for lung cancer screening (which has
proved to be ineffective) and currently as it is for prostate cancer
(Collins and Barry, 1996; Parkin and Pisani, 1999; Genta, 2004). No
controlled trial has been conducted, in our knowledge, to
determine the effectiveness of the Japanese model of gastric
cancer screening. Japan has made considerable investments in
X-ray mass-screening programme, achieving important reductions
in mortality (Oshima et al, 1986). Some critics, however, argue that
these reductions may be due to other reasons and that the only
effect of the screening programme has been to inflate the incidence
rates with cases that never would have evolved into advanced
cancer and death (Everett and Axon, 1998).
The impact of cancer screening interventions is difficult to
evaluate (Adami et al, 2001). Biases occur when screened
individuals are volunteers and probably self selected in terms of
lifestyles, including diet and preexistence of gastric problems
(Pisani et al, 1994). Over-diagnosis or pseudo-disease bias is a
problem too, that is, a disease discovered in screening campaigns,
but which would not have affected the patient had it not been
detected (Everett and Axon, 1998). When death is not the
evaluation end point, multiple biases occur as well and the
evidence is ‘inadmissible’ (Sackett et al, 1991; Alibhai, 2006).
Costa Rica has the second highest mortality rate and the fifth
highest incidence rate of stomach cancer in the world (Ferlay et al,
2001). Within Costa Rica, there are large differences, with the
highest rates of gastric cancer and of precancerous lesions
occurring in the country’s highlands (Salas, 1975; Sierra et al,
1989, 1995). Case fatality of stomach cancer in Costa Rica is very
high with a mortality/incidence ratio of 85%, which is more than
twice higher than the corresponding ratio in Japan (Ferlay et al,
2001). Case fatality is high because most diagnoses occur at
advanced stages of the disease: only 3– 7% of cases are diagnosed
in early stages and survival after 5 year is less than 15% (Sasagawa
et al, 1999).
A demonstrative gastric cancer, mass-screening programme in a
high-risk population, with the Japanese method as model, was
carried out in Costa Rica from 1996 to 2000 (Sasagawa et al, 2002).
This study evaluates the impact of this intervention, which was
designed as a community controlled, non-randomised, screening
programme. It presents results regarding the validity of the
screening programme. Then, following a cohort, quasi-experi-
mental design with measurements before and after, it assesses the
effect upon incidence, case survivorship, and mortality.
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PARTICIPANTS AND METHODS
The screening programme
The Costa Rican government, with assistance from the Japan
International Cooperation Agency (JICA), carried out a pilot
stomach cancer mass-screening intervention from 1996 to 2000. It
covered the region of Cartago and Los Santos, which is well known
for its high incidence of this disease (Sierra et al, 1995). The Max
Peralta Hospital, which is the regional, public hospital that covers
this region, hosted it. The ‘Cartago project’ followed procedures
developed in Japan for screening and treatment of gastric cancer.
The project conducted X-ray mass screening using upper
gastrointestinal tract high-resolution, double-contrast studies.
Trained X-ray technicians did the studies, using effervescent
granules and barium meal of high density. Two radiologists
examined the films. Participants with a suspicious abnormality
(cancer or, in most cases, other stomach lesions such as ulcers)
were sent for additional examination using high-resolution upper
videoendoscopy and, if necessary, gastric biopsies. Those with
gastric cancer were treated and followed up in the Max Peralta
hospital. Treatment included resection with or without lymph
node dissection. All studies and surgeries were performed with the
participation of Japanese staff using methods that are identical to
those used in Japan for detection, diagnosis, treatment, and stage
classification of gastric cancer (Sasagawa et al, 1999). The screened
individuals were invited to repeat the protocol after 2 years.
Regarding the radiation dose, the project’s equipment was
authorised by the corresponding authority as meeting the norms.
There was, however, no requirement of measuring or keeping
records of the radiation dose used on each individual.
Participants
Participants were not self-selected volunteers but those invited
from the general population. The project sent invitation letters to
the residents in the intervention region born between 1921 and
1945. In addition, eligible participants must have had no previous
diagnosis of gastric cancer. The intervention region was covered
taking one ‘health sector’ at a time. Health sectors are small areas
of less than 1000 households served with primary health care by a
team of health professionals named EBAIS. Invited individuals
were drawn from a census conducted earlier by the project or by
the EBAIS. To increase statistical power, only half of the eligible
women were randomly invited. From 15 to 20 participants were
invited daily. The project provided transportation to and from the
hospital. Participants gave informed consent in writing. The Ethics
Committee of the University of Costa Rica approved the study.
The first wave of mass screening took place from March 1996 to
March 1999, and the second wave, from March 1998 to June 2000.
Screening activities were suspended for 9 months in 1998–1999
because of construction works at the hospital.
The original study design was aimed at 12 000 participants to
have statistical power to detect 50% reduction in mortality after 4
years. The actual study, however, had only 7000 participants
because of the 9-month suspension, and productivity was lower
than the 30 daily screenings originally planned according to
Japanese parameters. We compensated this reduction by observing
mortality for a longer period: 7 years instead of 4. Also because of
this reduction in sample size, the intervention was not able to
cover the entire Cartago - Los Santos region.
Evaluation design and the control groups
The evaluation follows a quasi-experimental design (Mohr, 1988)
with an intervention group (the cases) and two control groups, as
well as before and after measurements. It is thus a nonrandomised
community-controlled trial. The first control group includes the
cohorts born in 1921–1945 and residing in the region of Pe´rez
Zeledo´n (PZ), a region that shares with Cartago the highest
incidence of stomach cancer in Costa Rica. PZ is located more than
100 kilometres South of Cartago; mountains separate the two
regions. The second control arm came from the same intervention
area of Cartago and Los Santos. This arm includes all intervention
cases until the date of their first screening visit (which on average
took place in May 1997) as well as residents in the originally
selected region who were not invited to the mass screening; that is
about 3000 women randomly left out and about 8000 eligible
residents in sub-areas that the project was not able to cover. We
did not include in this control arm approximately 2000 non-
respondents to the invitation.
For the impact evaluation exercise, we imposed two additional
eligibility conditions: (1) being a resident in the study regions
in 1990, and (2) being a Costa Rican citizen. The study indivi-
duals should have been included in the 1990 voting registry
of the study regions and all must have a unique identification
number (the ce´dula), which would allow us to follow them in
computer files of the death registry and the national tumour
registry.
There are thus four control arms, as described in Table 1: (1)
Cartago-before, with about 20 000 individuals; (2) Cartago-after,
11 000; (3) PZ-before, 12 000; and (4) PZ-after, 11 000. Each
individual contributes 6 or 7 years of observation to each arm.
The number of screening cases in the evaluation (6200) is smaller
than the total number of participants due to the additional
eligibility criteria of being a Costa Rican citizen and a resident in
the region by 1990. The after control groups, as well as the
intervention group, are about 6 years older than the before groups,
reflecting the time elapsed. The intervention group has more men
(64%) and the Cartago-after has fewer men (42%) by design, as
50% of women were randomly excluded from the intervention.
These age and sex differences must be controlled for in the
analyses. Socioeconomic status, as measured by the percentages
Table 1 The case and control groups for the evaluation
Indicator Cases Control 1 Control 2 Control 3 Control 4
Region Cartago Cartago Cartago PZ PZ
Timing After Before After Before After
Entry date X-ray visit 1 January 1991 May 1997 January 1991 May 1997
Exit date December 2004 Visit 1 or May 1997a December 2004 May 1997 December 2004
N participants 6206 20 030 11 190 11 915 11 318
N person-years 45 231 123 121 80 630 73 666 82 408
Males 64% 51% 42% 51% 51%
Mean age 64.3 57.9 64.3 58 64.6
High school education 7.8% — 8.6% — 8.1%
Have refrigerator 86% — 90% — 83%
PZ¼ Pe´rez Zeledo´n. aObservation in this group ends (it is censored) at the date of the first screening visit if the individual became a ‘case’ or in May 1997 if he did not.
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with high school education and possessing a refrigerator, differs
little among groups (Table 1).
For evaluation purposes, we further distinguish in the inter-
vention group the 2 years following the first screening visit from
the period afterwards. Cancer gastric mortality in this initial
period is probably biased by the eligibility requirement of being
free of the disease. (Because the intervention group cannot include
cases of individuals with gastric cancer diagnosis, very few deaths,
if any, due to this disease will occur in the months following the
screening.) In turn, early detection of cancer lesions will help avoid
deaths only after several months or years have passed since the
screening date. In an extreme situation, if the screening detects
very early lesions, which would have progressed to metastatic
disease in say, 5 years, we should wait at least 5 years to evaluate
the impact. In this study, the waiting period is 2 years.
The data
We used four major sources of information.
1. The Cartago project databases, which provided the dates of the
screening procedures, waves 1 and 2, and the diagnoses of these
procedures.
2. The 1990 Voting Registry (padro´n electoral) to identify the
study individuals, cases, or controls, with their identification
number. The Tribunal Supremo de Elecciones (TSE) provided
the database.
3. The 1990–2004 Death Registry to determine the dates and
causes of death of deceased individuals. The TSE also provided
this database.
4. The 1990– 2004 National Tumor Registry to find out all the
stomach cancer cases and their diagnoses dates. The Ministry of
Health provided the computer data file.
Validity assessment
All participants in the intervention were included in a validity
assessment of sensitivity, specificity, and positive predictive value.
With data from the tumour registry, we consider incident cases of
all those diagnosed within 18 months from the X-ray screening
visit. We consider ‘screening positives’ to individuals who went to
endoscopy, regardless of whether or not they were ‘cancer suspect.’
In a second, hypothetical estimate, we consider positives only to
those rated ‘cancer suspect’ in the X-ray exam. Note that many
cancers were detected in participants sent to endoscopy because of
no cancer gastric pathologies.
Survival
We compare Kaplan–Meier survival curves of stomach cancer
cases to assess the effect of the intervention upon survivorship.
These curves show the proportion of individuals alive over time
starting at the time the cancer was diagnosed and with correction
for ‘censoring’ (Hosmer and Lemeshow, 1999).
Incidence and mortality
We compared incidence or mortality rates in the intervention
group with the standardised rates in the four control groups. The
age (5-year brackets) and sex structure of the intervention group
was the standard. We used ‘robust’ estimates of the 95%
confidence intervals for these rates, which takes into account that
several observation years come from the same individual
(Statacorp, 2005).
The final estimate of impact comes from a proportional hazard
model, also known as Cox regression, on the gastric cancer death
hazard function (Hosmer and Lemeshow, 1999). We used the Stata
software to estimate the model, with birth date as the origin and
January 1991 as the entry date of observation. Data were censored
at the following three events: (1) death by causes other than
stomach cancer, (2) first screening visit or May 1997 for the
‘before’ groups, and (3) December 2004 for the ‘after’ groups. In
addition, for the first two years of the intervention, the censoring
date was the second anniversary of the first screening visit. The
death rate ratios estimated with the model measure the impact of
the intervention. Since no second-order interaction terms were
found significant in preliminary estimates of the regression model,
we excluded them.
RESULTS
About 7000 participants went through the first X-ray screening
procedure (Table 2). Five thousand returned for a second wave of
screening 2 years later. Non-response to the first invitation and
attrition in the second were reasonably low: 22 and 25%,
respectively.
The X-ray series detected gastric pathologies meriting an
endoscopy in 34% of participants in the first wave and in 20%
in the second wave (Table 2). Most lesions were gastritis, peptic
ulcers, and hernias. Our broad operational definition of positive
test is the sending of an individual to endoscopy. Most of these
‘positive X-rays’, however, had no diagnosis of cancer. After
endoscopy and histopathology diagnoses, the project detected 59
gastric cancers in the first wave and 28 in the second wave. Ten
cancers went undetected by the project: six in the first wave and
four in the second wave. These undetected cases were diagnosed
outside the project within 18 months of the X-ray examination. It
is worth noting, however, that all but one of these ‘false negatives’
went through the endoscopy procedure, and four cases had a
biopsy. One case had a histopathology diagnosis of ‘suspicious
cancer’, but did not return to surgery for a final diagnosis.
After surgery, and following Japanese classification criteria, 62%
of cancers were at early stage, 55% in the first wave and 80% in the
second wave (Table 2).
Table 2 Main results and validity of the screening
Item Wave 1 Wave 2
N invited 8705 6769
N screened 6828 5046
% non-response/attrition 22% 25%
Screening results
% sent to endoscopy – total 34% 20%
Because cancer suspect 3% 2%
With other pathologies 31% 18%
Stomach cancer cases
N detected 59 28
N undetected 6 4
Cancer detected at early stage 55% 80%
X-ray validity indicatorsa
Sensitivity 91% 88%
Specificity 67% 80%
Positive predictive value 3% 3%
Hypothetical restrictedb screening
Sensitivity 58% 47%
Specificity 98% 98%
Positive predictive value 19% 16%
aAll sent to endoscopy are taken as positives. bIf only cancer suspicious participants
were sent to endoscopy.
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Validity
Taking the screening programme in its entirety, sensitivity was
91% in the first round and 88% in the second wave. As noted, most
false negatives occurred in the endoscopy procedure or in the
histopathology diagnosis. Specificity of the X-ray procedure was
67% in the first wave, and improved to 80% in the second wave.
The positive predictive value of the intervention was just 3%
(Table 2).
This moderate specificity comes from our operational definition
of X-ray ‘positives’ as all who went to endoscopy for any reason. In
actuality, only about 10% of them went under suspicion of cancer.
If we define positives as those who had the diagnosis ‘suspicious of
cancer’ in the X-ray examination (202 participants in the first
round and 96 in the second), the specificity climbs to 98% (last
panel of Table 2). The positive predictive value also improves to
19%. The problem, however, is that many of the cancers diagnosed
by the programme were among participants sent to endoscopy
because of other pathologies. In the hypothetical situation that the
programme would have sent to endoscopy only ‘suspicious of
cancer’ subjects, sensitivity would have dropped to a dismaying
58%.
Incidence
If a screening programme is having an impact, incidence must
increase in the intervention group, at least in the short term. About
100 gastric cancer cases occurred in the screened group between
the entry-time in the project and December 2002. The correspond-
ing incidence rate of 56 per 10 000 person-years is clearly higher
than the rates in the four control groups (Figure 1). Incidence in
the screened group is about four times higher than the rate before
the intervention in the two study areas. The higher incidence
narrows when the comparison is with the after control groups. The
confidence intervals in Figure 1 show that the higher incidence in
the screened group is statistically significant, except when
compared to the Cartago after group. In both Cartago and PZ
control areas, incidence increased over time.
Case survival
If a screening programme is having an impact, it must show that
case survival has improved. Figure 2 shows the Kaplan–Meier
survival curve (adjusted for age and sex) for cases in the
intervention and the four control groups (group size ranges
between 70 and 129 cases). The survival curve of the screened
group is remarkably higher than those of the control groups. Five-
year survival in the intervention arm was 80% or 86% after
adjustment for age and sex. Comparable figures for the control
groups range from 12% in Cartago before to 35% in Cartago after.
Further distinguishing early and late cancers in the intervention
group (Japanese classification of stage of disease, Sasagawa et al,
1999), 5 year survival is comparatively high in both groups: 95%
for early cases and 77% for late cancer stage at diagnosis (figures
adjusted for age and sex). Both early- and late-stage survival curves
of the intervention group (not shown in figures) are significantly
higher than the four control groups. Survival in early cancers at
detection is also significantly higher than that in cancers detected
at late stages. Unfortunately, there is no comparable information
on stage of disease for the control groups, although from earlier
studies we know that the great majority of gastric cancers normally
diagnosed in Costa Rica are at late or advanced stage.
As with incidence, case survival increased over time in the two
control areas, especially in Cartago. The improvement in survival
in Cartago (excluding the screened group) is statistically
significant; the improvement in PZ is not so. There are no
significant differences between PZ and Cartago in the curves of the
before period.
Mortality
Twenty-six screened individuals died of gastric cancer during the
evaluation period of 2 –7 years post-screening, at a rate of 8 per
10 000 person-years (Figure 3). This rate is substantially lower than
the rates in the four control groups. In relative terms, it ranges
between 0.41 and 0.52 of the control rates. The confidence intervals
show that these effects are statistically significant. Depending on
which control arm is taken as comparison, the intervention would
have avoided between 24 and 37 deaths over the 5-year evaluation
period. Figure 3 also suggests a decline over time in gastric cancer
Cartago after
Screened
Cartago
before
PZ before
PZ after
0 20 40 60 80
Adjusted gastric cancer incidence rate per 10000
Figure 1 Gastric cancer incidence rates adjusted by age and sex to the
screened population (95% confidence intervals shown).
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Figure 2 Kaplan–Meier survival curves of stomach cancer cases in the
screened and control groups. Curves adjusted to age 60 and males.
Screened 2+
years
Screened <2
years
Cartago
before
Cartago
after
PZ before
PZ after
5 10 15 20 25
Adjusted gastric cancer death rate per 10000
0
Figure 3 Gastric cancer death rates adjusted by age and sex to the
screened population (95% confidence intervals shown).
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mortality in both control areas, especially in Cartago, although this
trend is not statistically significant.
The Cox regression results provide more precise estimates. The
death rate ratios estimated with the regression model show that the
risk of death by gastric cancer among controls is 2.1 and 1.7 times
higher than in the cases before and after the intervention,
respectively (Table 3). The model also shows that males die at
rates more than twice those of women. It also suggests that
mortality is a bit higher in Cartago than in PZ and that mortality is
declining in more recent cohorts, although these effects are not
statistically significant. The regression model controls the poten-
tially confounding effects of cohort, sex, and region of residence.
Cox-regression models also implicitly control the effect of ageing.
In the Cox model, as well as in Figure 3, mortality in the first 2
years’ post-screening is lower than in the control groups and
slightly higher than in the evaluation period of 2– 7 years. These
differences are not, however, statistically significant, which in part
is due to the lack of statistical power (large confidence intervals).
DISCUSSION
An X-ray screening pilot intervention apparently halved gastric
cancer mortality in a community controlled trial in Costa Rica. The
two-wave, double-contrast X-ray examination also increased the
incidence of gastric cancer diagnosis and substantially improved
case survival. We have estimated these effects using a quasi-
experimental, community evaluation design with before and after
measures.
Two improvements in the design of this study set it apart from
previous evaluations of X-ray screening of gastric cancer. First, the
intervention group comes from the general population. They did
not volunteer but were invited to participate as a sample of the
general population, minimising self-selection biases. Second, the
end-point evaluation is mortality, as mandatory for assessing
the impact of screening interventions.
Incidence (and stage of disease)
The Cartago project improved detection of gastric cancer. There
are two ways of reaching this conclusion. One is by looking at the
stage of the detected cancers, which has been done in an early
report of this intervention (Sasagawa et al, 1999). If most of them
were in early stages, there is an indication that the programme is
indeed highlighting cases that would have gone undetected without
the programme. Sasagawa et al (1999) show that 64% of stomach
cancer cases were diagnosed in early stages in the intervention
group, a proportion similar to the results obtained in Japan,
whereas in the rest of the population in the same region, served by
the same medical team, and in the same hospital, only 30% of
gastric cancer cases were detected in early stages. This proportion
was only 3–7% before the intervention in Cartago. Unfortunately
we do not have information on the stage of disease in the control
groups for analysing this topic in detail.
Another way of approaching this issue is by comparing
incidence in the screened group with incidence in the control
groups. The higher incidence (up to four-fold) in the intervention
group indicates that the project is catching additional cases. This
estimate comes from comparisons with the control groups before
the intervention. Comparison with controls contemporary to the
intervention renders a smaller increment, although this result may
be biased by ‘contamination’ among the controls, especially in the
Cartago area, as suggested by the increased incidence from the
before to after periods within each control arm. The intervention
was accompanied by ample diffusion of information about the
project, as well as about gastric cancer in general, between both
health professionals and lay public. In addition, the Cartago
project trained several technicians and physicians from other
hospitals in gastric cancer screening procedures. This information
diffusion could motivate individuals and physicians not in the
project to increase the use of screening practices resulting in the
aforementioned increased incidence with time.
Case survival
A screening programme that just detects more cases of early
cancer would be useless if it is not complemented with proper
treatment that extends life expectancy. The increased 5-year case
survival to 85% in the intervention group may be the result of both
early detection (see discussion below about the ‘lead time bias’)
and improved treatment. Prognosis of early gastric cancer is very
good worldwide. The Japanese treatment model with radical
surgery seems to be successful in extending life expectancy
(Everett and Axon, 1997). In this regard, the substantial increase
of 5-year survival among the Cartago controls may be a positive
side effect (a sort of contamination) from the intervention. The
surgery technique brought by the Japanese surgeons to the project
was used in the Cartago hospital in all gastric cancer patients and
not confined to the project’s cases.
An intriguing result is the high survival (77% after 5 years) of
late stage cancer cases diagnosed in the intervention, which was
much higher than in any control arm. A plausible explanation for
this is that even these late stage cancers were less advanced
compared to those normally diagnosed in Costa Rica and in the
control arms.
Mortality
The high survival curve of screened cases, although encouraging, is
not a proof of an impact. ‘Lead time bias’ is a well-known problem
with survivorship of cases uncovered with screening: they live
longer because they have been diagnosed earlier than unscreened
cases (as noted before, 64% of cancers in the intervention group
were in early stages). There could even be an ‘overdiagnosis bias’ if
the screening procedure detects early pseudo-cancers that, left
alone, never will evolve into advanced stages or they will evolve so
slowly that the person will die of some other disease. This is the
main reason why it is so important to evaluate mortality impact.
About 50% lower mortality in the screened group compared to the
control arms is a strong evidence that the screening intervention
had an impact. This effect is a bit lower when we compare
mortality with controls after the intervention. If lead time and
overdiagnosed biases are operating, most of the reported results
(higher incidence, higher survival, and earlier disease stage) would
be present. The drop in mortality, however, cannot be explained
for these common biases in screening interventions.
How robust is this impact estimate? We used the second best
evaluation design: quasi-experimental (Bertrand et al, 1996).
Although individuals were not randomly assigned to the interven-
tion or control group (although women were randomly invited to
Table 3 Cox regression estimates of mortality rate ratios in the
screening programme
Variable Rate ratio (95% CI)
Birth cohort (1 birth year) 0.97 (0.93 – 1.02)
Males (reference females) 2.13 (1.77 – 2.59)
Cartago (reference PZ) 1.12 (0.93 – 1.35)
Screening groups
Unscreened before 2.06 (1.23 – 3.46)
Unscreened after 1.73 (1.18 – 2.53)
Screened o2 years 1.24 (0.63 – 2.45)
Screened 2–7 years 1.00 Reference
CI¼ confidence interval; PZ¼ Pe´rez Zeledo´n.
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participate), participants were not allowed to volunteer. We are not
able to identify any reason, other than the screening itself, for the
intervention group to have 50% lower gastric cancer mortality.
Four pieces of information suggest that we have not selected an
intervention group that is biased with low gastric cancer mortality:
(1) Data for the period before the intervention show that the
intervention area of Cartago had a slightly higher mortality than
the control area of PZ, in contrast with the lower mortality of the
screened group compared to PZ. (2) Mortality did not increase in
the Cartago control arm, as would have happened if we had
selected a low-mortality subgroup for the intervention (Figure 3).
(3) The groups are comparable in terms of age, socioeconomic
status, and, most importantly, gastric cancer incidence and
mortality. Moreover, the Cox regression model controlled for
differences in gastric cancer mortality by age, sex, or region. (4)
The high response rate of 78% makes self-selection or volunteer
bias unlikely, although it is still an issue. In this regard, the data for
non-respondents shows that their gastric cancer mortality is higher
than among the screened individuals and slightly higher (non
significantly) than the control group. Including about 2000 refusals
in the ‘after’ control arm, the rate ratio of this group in the Cox
regression is 1.85 compared with the 1.73 original estimate, that is
results are not sensitive to the decision of excluding non-
respondents from the control-after arm.
In spite of all this strong evidence, our conclusions cannot be
definitive as the intervention was not a randomised trial. In
addition, the length of observation for mortality (from 2 to 7 years)
may not be long enough if the cases were at a very early stage. We
will continue following the study arms several years in the future to
assess the long-term effects.
Readers from developed countries may question that we used
the national registries of deaths and tumours to track incidence
and mortality. It is very difficult to prove that both registries have
complete coverage in Costa Rica even though no study has proved
the contrary. Not only is coverage complete but also the quality of
information on cause of death and tumour location is valid given
that 98% of deaths have a medical certificate and the tumour
registry is histology based. The good quality of the Costa Rican
statistical system goes along with an outstanding and universal
healthcare system that has achieved the second highest national
life expectancy in the continent (Canada has the highest), higher
even than the United States (World Bank, 2006). Moreover, even if
these registries had deficiencies, it is not clear how these could
affect our results given that we are using the same sources of
information for both the intervention and control groups. If errors
in recording gastric cancer deaths were biased within our groups,
this would be in the direction of omitting relatively less deaths in
the intervention group given the fact that these individuals were
under close scrutiny by the project.
Our decision to exclude from the evaluation the first 2 years
after screening may raise objections. Reestimating the Cox
regression model without this exclusion results in effects that are
only slightly smaller than those originally reported: a mortality
reduction of 48% with respect to the controls before and of 38%
with respect to the controls after, compared to the 51 and 42%
originally reported.
Validity of X-rays as screening test
It is obviously desirable to have a screening test that is both highly
specific and highly sensitive. In practice, however, there is usually
a trade-off between the sensitivity and specificity of a test. The
Japanese screening model implemented in Costa Rica opted for
high sensitivity (about 90%) at the expense of a somehow poor
specificity (67% in first visit, 80% after two visits). This result was
a conscious choice of the intervention physicians and came from
the practice of sending to endoscopy not only those who appeared
suspicious of cancer but many participants with gastric patholo-
gies (mostly ulcers, ulcer scars, hernias, and gastritis). This
practice had adverse effects in terms of cost and the discomfort
caused to many, but it also allowed more cancers to be detected
and treated and helped improve the health of many individuals.
These positive impacts of the screening intervention were not
evaluated in this study.
Other adverse effects may come from the radiation of the X-ray
examination, although the project used cutting edge technology
equipment that warrants very low doses of radiation. The
unnecessary stress in the many ‘false-positive’ individuals also
can be accounted as an adverse effect, although participants were
clearly informed that those not suspicious of cancer would also be
sent to endoscopy. And there is the possibility of complications
from the endoscopy and biopsy examinations, including bleeding,
perforation, infection, and others. It is estimated that one in 1000
procedures has these type of complications. The project did not
record systematically the occurrence of these adverse events. The
only serious complication reported in the project was an
oesophagus perforation in a participant with advanced cancer.
It must be noted, however, that our estimates of sensitivity and
specificity are not based on a parallel gold standard for all screened
participants, but on national tumour registry and death data,
which are not perfect.
Policy implications
A health intervention with the potential for reducing gastric cancer
mortality by 50% seems extraordinarily attractive in particular,
considering that this is the second most lethal cancer worldwide,
and the first one in some countries like Costa Rica. Some
cautionary notes are however in place. First, the Cartago project
was a pilot intervention, implemented under quite controlled
circumstances and with an unusual wealth of resources, including
manpower and equipment provided free by the government of
Japan as well as unusually abundant academic and medical
resources provided by Costa Rican institutions. Second, the 50%
impact is restricted to just the screened population. A full scale,
mass-screening programme will hardly be able to cover the totality
of the population. Third, the cost of an X-ray mass-screening
programme including treatment and other side activities is not
cheap.
A cost estimate of the pilot programme resulted in about
US$1.000 per examination or, assuming 30 avoided deaths,
$300.000 per saved life (Schram, 2005). These figures are, of
course, inflated by the high costs of Japanese personnel. It seems
feasible to halve the costs by using only national manpower and
improving productivity and screening technology. However, the
law of decreasing yields will start to operate when the intervention
is scaled up to cover populations with lower cancer incidence than
the pilot group (i.e., lower ages, more women, and regions other
than Cartago). In any scenario, the costs of the screening program
seem far too high in a country like Costa Rica where yearly health
expenditures are in the order of $300 per capita (World Bank,
2006). A new promising, affordable screening test for gastric
cancer is serum pepsinogens (Miki et al, 2003; Dinis-Ribeiro et al,
2004; Oishi et al, 2006). This new screening test must, however, be
evaluated in studies like the one in this study.
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